Home › Funds › Avidity Partners Management LP › KPTI

Avidity Partners Management LP position in KPTI

KARYOPHARM THERAPEUTICS INC · Health Care

Avidity Partners Management LP reported holding 924,487 shares of KPTI (KARYOPHARM THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$9.0M, representing 1.45% of its reported portfolio and ranking #13 among its reported holdings. Avidity Partners Management LP has disclosed KPTI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)924.49K sh
Reported value held$9.03M
Portfolio Weight1.45%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Avidity Partners Management LP's KPTI position evolved

Avidity Partners Management LP first disclosed a stake in KPTI in Q3 2023 at 8,298,570 shares (US$11.1M). The position peaked in Q1 2024 at 8,298,570 shares, worth US$12.5M. Across 12 filings, Avidity Partners Management LP increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 924,487 shares valued at US$9.0M — an increase of 460,746 shares quarter over quarter.. Notable position changes include a 93% trim in Q1 2025 (shares rose 15% over the following quarter), a 245% increase in Q1 2026 (shares rose 75% over the following quarter), a 99% increase in Q2 2026 (shares fell 88% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 8.30M $11.12M New
Q4 2023 8.30M $7.18M Hold
Q1 2024 8.30M $12.53M Hold
Q2 2024 2.02M $1.75M Reduce
Q3 2024 2.02M $1.68M Hold
Q4 2024 2.02M $1.37M Hold
Q1 2025 134.57K $503.28K Reduce
Q2 2025 134.57K $579.98K Hold
Q3 2025 134.57K $880.06K Hold
Q4 2025 134.57K $990.41K Hold
Q1 2026 463.74K $2.58M Add
Q2 2026 924.49K $9.03M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KPTI and 13F data

KPTI (KARYOPHARM THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in KPTI — the largest reported positions include ACORN CAPITAL ADVISORS, LLC (US$14.8M), Catalio Capital Management, LP (US$9.2M), Kalehua Capital Management LLC (US$6.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KPTI

All KPTI fund holders →

FAQ

How long has Avidity Partners Management LP held KPTI?

Avidity Partners Management LP has disclosed KPTI holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Avidity Partners Management LP's current position in KPTI?

As of Q2 2026, Avidity Partners Management LP holds 924.49K shares of KPTI (KARYOPHARM THERAPEUTICS INC), valued at $9.03M, representing 1.45% of its reported portfolio and ranking #13.

Has Avidity Partners Management LP been buying or selling KPTI?

In the latest 13F filing (Q2 2026), Avidity Partners Management LP increased its position in KPTI. The position peaked in Q1 2024 at 8.30M shares.

Which other funds hold KPTI?

Other major institutional holders of KPTI include ACORN CAPITAL ADVISORS, LLC, Catalio Capital Management, LP, Kalehua Capital Management LLC, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.